|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CKAP2 |
Gene summary for CKAP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CKAP2 | Gene ID | 26586 |
| Gene name | cytoskeleton associated protein 2 | |
| Gene Alias | LB1 | |
| Cytomap | 13q14.3 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q8WWK9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26586 | CKAP2 | LZE4T | Human | Esophagus | ESCC | 1.86e-06 | 3.10e-01 | 0.0811 |
| 26586 | CKAP2 | LZE7T | Human | Esophagus | ESCC | 1.52e-06 | 2.49e-01 | 0.0667 |
| 26586 | CKAP2 | LZE24T | Human | Esophagus | ESCC | 1.40e-11 | 3.01e-01 | 0.0596 |
| 26586 | CKAP2 | LZE21T | Human | Esophagus | ESCC | 1.31e-02 | 2.42e-01 | 0.0655 |
| 26586 | CKAP2 | LZE6T | Human | Esophagus | ESCC | 4.54e-04 | 1.85e-01 | 0.0845 |
| 26586 | CKAP2 | P1T-E | Human | Esophagus | ESCC | 1.09e-05 | 4.76e-01 | 0.0875 |
| 26586 | CKAP2 | P2T-E | Human | Esophagus | ESCC | 2.93e-25 | 7.54e-01 | 0.1177 |
| 26586 | CKAP2 | P4T-E | Human | Esophagus | ESCC | 3.38e-26 | 8.19e-01 | 0.1323 |
| 26586 | CKAP2 | P5T-E | Human | Esophagus | ESCC | 1.81e-10 | 3.98e-01 | 0.1327 |
| 26586 | CKAP2 | P8T-E | Human | Esophagus | ESCC | 1.49e-03 | 2.28e-01 | 0.0889 |
| 26586 | CKAP2 | P9T-E | Human | Esophagus | ESCC | 4.76e-08 | 3.67e-01 | 0.1131 |
| 26586 | CKAP2 | P10T-E | Human | Esophagus | ESCC | 9.01e-20 | 6.46e-01 | 0.116 |
| 26586 | CKAP2 | P11T-E | Human | Esophagus | ESCC | 1.66e-03 | 1.88e-01 | 0.1426 |
| 26586 | CKAP2 | P12T-E | Human | Esophagus | ESCC | 3.34e-17 | 4.43e-01 | 0.1122 |
| 26586 | CKAP2 | P15T-E | Human | Esophagus | ESCC | 1.51e-10 | 3.41e-01 | 0.1149 |
| 26586 | CKAP2 | P16T-E | Human | Esophagus | ESCC | 3.41e-13 | 3.70e-01 | 0.1153 |
| 26586 | CKAP2 | P17T-E | Human | Esophagus | ESCC | 6.41e-09 | 6.91e-01 | 0.1278 |
| 26586 | CKAP2 | P19T-E | Human | Esophagus | ESCC | 1.01e-04 | 5.37e-01 | 0.1662 |
| 26586 | CKAP2 | P20T-E | Human | Esophagus | ESCC | 5.41e-30 | 8.10e-01 | 0.1124 |
| 26586 | CKAP2 | P21T-E | Human | Esophagus | ESCC | 3.08e-17 | 5.84e-01 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
| GO:003298416 | Esophagus | ESCC | protein-containing complex disassembly | 151/8552 | 224/18723 | 3.45e-11 | 1.15e-09 | 151 |
| GO:1902903111 | Esophagus | ESCC | regulation of supramolecular fiber organization | 237/8552 | 383/18723 | 9.06e-11 | 2.75e-09 | 237 |
| GO:000028115 | Esophagus | ESCC | mitotic cytokinesis | 58/8552 | 71/18723 | 4.34e-10 | 1.15e-08 | 58 |
| GO:0010639110 | Esophagus | ESCC | negative regulation of organelle organization | 215/8552 | 348/18723 | 8.20e-10 | 2.01e-08 | 215 |
| GO:000091016 | Esophagus | ESCC | cytokinesis | 115/8552 | 173/18723 | 2.48e-08 | 4.68e-07 | 115 |
| GO:006164015 | Esophagus | ESCC | cytoskeleton-dependent cytokinesis | 72/8552 | 100/18723 | 8.10e-08 | 1.39e-06 | 72 |
| GO:00705078 | Esophagus | ESCC | regulation of microtubule cytoskeleton organization | 99/8552 | 148/18723 | 1.43e-07 | 2.29e-06 | 99 |
| GO:00311094 | Esophagus | ESCC | microtubule polymerization or depolymerization | 77/8552 | 122/18723 | 7.60e-05 | 5.68e-04 | 77 |
| GO:00432446 | Esophagus | ESCC | regulation of protein-containing complex disassembly | 75/8552 | 121/18723 | 2.17e-04 | 1.36e-03 | 75 |
| GO:00311104 | Esophagus | ESCC | regulation of microtubule polymerization or depolymerization | 57/8552 | 88/18723 | 2.32e-04 | 1.44e-03 | 57 |
| GO:00328864 | Esophagus | ESCC | regulation of microtubule-based process | 134/8552 | 240/18723 | 9.44e-04 | 4.80e-03 | 134 |
| GO:00436245 | Esophagus | ESCC | cellular protein complex disassembly | 78/8552 | 136/18723 | 4.00e-03 | 1.62e-02 | 78 |
| GO:002241112 | Liver | HCC | cellular component disassembly | 282/7958 | 443/18723 | 1.02e-19 | 1.38e-17 | 282 |
| GO:190290322 | Liver | HCC | regulation of supramolecular fiber organization | 224/7958 | 383/18723 | 1.54e-10 | 5.33e-09 | 224 |
| GO:001063912 | Liver | HCC | negative regulation of organelle organization | 204/7958 | 348/18723 | 7.67e-10 | 2.37e-08 | 204 |
| GO:003298411 | Liver | HCC | protein-containing complex disassembly | 138/7958 | 224/18723 | 5.59e-09 | 1.46e-07 | 138 |
| GO:000028111 | Liver | HCC | mitotic cytokinesis | 51/7958 | 71/18723 | 5.20e-07 | 8.38e-06 | 51 |
| GO:007050711 | Liver | HCC | regulation of microtubule cytoskeleton organization | 88/7958 | 148/18723 | 2.28e-05 | 2.41e-04 | 88 |
| GO:000091011 | Liver | HCC | cytokinesis | 100/7958 | 173/18723 | 3.38e-05 | 3.39e-04 | 100 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CKAP2 | SNV | Missense_Mutation | novel | c.1303N>G | p.Asn435Asp | p.N435D | Q8WWK9 | protein_coding | tolerated(0.13) | possibly_damaging(0.616) | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| CKAP2 | SNV | Missense_Mutation | rs775705785 | c.383C>T | p.Pro128Leu | p.P128L | Q8WWK9 | protein_coding | tolerated(1) | benign(0) | TCGA-A2-A3KC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| CKAP2 | SNV | Missense_Mutation | novel | c.1739C>A | p.Pro580His | p.P580H | Q8WWK9 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| CKAP2 | SNV | Missense_Mutation | novel | c.304N>T | p.Pro102Ser | p.P102S | Q8WWK9 | protein_coding | tolerated(0.16) | probably_damaging(0.998) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
| CKAP2 | SNV | Missense_Mutation | c.1914N>T | p.Leu638Phe | p.L638F | Q8WWK9 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AQ-A0Y5-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD | |
| CKAP2 | SNV | Missense_Mutation | c.638N>A | p.Pro213His | p.P213H | Q8WWK9 | protein_coding | deleterious(0.04) | possibly_damaging(0.724) | TCGA-BH-A0C0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
| CKAP2 | SNV | Missense_Mutation | novel | c.1390T>C | p.Trp464Arg | p.W464R | Q8WWK9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CKAP2 | SNV | Missense_Mutation | c.1658N>G | p.Leu553Arg | p.L553R | Q8WWK9 | protein_coding | tolerated(0.46) | benign(0) | TCGA-C8-A133-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| CKAP2 | SNV | Missense_Mutation | c.1516N>G | p.Leu506Val | p.L506V | Q8WWK9 | protein_coding | deleterious(0.01) | benign(0.415) | TCGA-C8-A26V-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | CR | |
| CKAP2 | SNV | Missense_Mutation | novel | c.902A>G | p.Lys301Arg | p.K301R | Q8WWK9 | protein_coding | deleterious(0.03) | possibly_damaging(0.864) | TCGA-S3-AA11-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | CR |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |